Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2008 Jul 17;28(10):1811–1819. doi: 10.1161/ATVBAHA.108.167908

FIGURE 3. 12/15LO products enhance ABCG1 degradation.

FIGURE 3

Panel A. Left, J774 macrophages were treated with either vehicle control (CTR), arachidonic (AA), or linoleic (LA) acids for 2 hours prior to the addition of cycloheximide for the indicated time points. Cell lysates were analyzed by immunoblotting for ABCG1. Right, Densitometry of immunoblot normalized to beta actin. Data represent the mean ± SE of 3 experiments (*significantly lower than CTR 60min p<0.002 by ANOVA). Panel B. Left, J774 macrophages were treated with cycloheximide and either vehicle control (CTR), 12SHETE, or 15SHETE for the indicated time points. Cell lysates were analyzed by immunoblotting for ABCG1. Right, Densitometry of immunoblots normalized to beta actin. Data represent the mean ± SE of 3 experiments (*significantly lower than CTR 30min p<0.003; #significantly lower than CTR 60min p<0.05 by ANOVA).